Additional reporting of diffuse and homogeneous ROS-1 SP384 immunoreactivity enhances prediction of ROS1 fusion–positive non-small cell lung cancer
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae118 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Bokyung Ahn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins. Die Arbeit nennt 29 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Objectives
ROS-1 immunohistochemistry (IHC) is a common method for screening ROS1 fusion in the clinical management of non-small cell lung cancer. The interpretation criteria for ROS-1 SP384 IHC, however, remain unestablished.
Methods
Sixty-five non-small cell lung cancer cases underwent AmoyDx ROS1 fusion real-time polymerase chain reaction (PCR) study and ROS-1 SP384 IHC tests, which were retrieved for analysis. ROS-1 IHC tests were interpreted based on the established classifiers as well as the presence of diffuse homogeneous immunoreactivity. The diagnostic accuracies of these ROS-1 IHC interpretation methods were evaluated by comparing them with the ROS1 real-time PCR results.
Results
Previous ROS-1 IHC classifiers demonstrated high sensitivity for positive ROS1 real-time PCR results (100%), but they showed low specificities (25%-50%) and overall accuracies (58%-72%). In contrast, the diffuse homogeneous ROS-1 immunoreactivity predicted positive ROS1 real-time PCR results with much higher specificity (94%) and overall accuracy (95%), albeit with a slightly lower sensitivity (97%). Some cases that showed discrepancy between diffuse homogeneous ROS-1 immunoreactivity and real-time PCR results involved rare ROS1::LDLR fusion and suboptimal IHC staining.
Conclusions
A 3-tier reporting system for ROS-1 SP384 IHC testing combining previous interpretation criteria and diffuse and homogeneous immunoreactivity may better predict ROS1 fusion status without decreasing specificity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Ahn, B., Jang, S. J., & Hwang, H. S. (2025). Additional reporting of diffuse and homogeneous ROS-1 SP384 immunoreactivity enhances prediction of ROS1 fusion–positive non-small cell lung cancer. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae118
Vancouver
Ahn B, Jang SJ, Hwang HS. Additional reporting of diffuse and homogeneous ROS-1 SP384 immunoreactivity enhances prediction of ROS1 fusion–positive non-small cell lung cancer. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae118
BibTeX
@article{Ahn2025,
author = {Ahn, Bokyung and Jang, Se Jin and Hwang, Hee Sang},
title = {Additional reporting of diffuse and homogeneous ROS-1 SP384 immunoreactivity enhances prediction of ROS1 fusion–positive non-small cell lung cancer},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae118}
}
EUVIMED